UHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Universal Health Services Inc (UHS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a downtrend, with bearish technical indicators and increased insider selling activity. While the company's financial performance in the latest quarter shows strong growth, the mixed analyst ratings, weak trading sentiment, and lack of significant positive catalysts suggest that waiting for a better entry point may be prudent.
The MACD is negatively expanding (-4.002), indicating bearish momentum. RSI is at an oversold level (13.359), suggesting potential for a short-term bounce but not strong enough for a reversal. Moving averages are converging, signaling indecision. The current price is below key support levels (S1: 194.176), with the next support at S2: 183.587, indicating further downside risk.
The company's financial performance in Q4 2025 showed strong growth, with revenue up 9.05% YoY, net income up 34.16% YoY, and EPS up 42.34% YoY. UBS raised the price target to $320, reflecting optimism in the healthcare sector.
Insiders are selling heavily, with a 291.34% increase in selling activity over the last month. Analysts have mixed ratings, with some lowering price targets due to weak core results and concerns over acute business performance. The MACD and RSI indicate bearish momentum, and the stock is trading below key support levels. Options data also reflects bearish sentiment.
In Q4 2025, Universal Health Services reported revenue of $4.49 billion, up 9.05% YoY. Net income increased to $445.94 million, up 34.16% YoY. EPS rose to $7.06, up 42.34% YoY. Gross margin remained flat at 100%.
Analyst ratings are mixed. UBS raised the price target to $320 with a Buy rating, while Wells Fargo lowered the target to $212 with an Equal Weight rating. Cantor Fitzgerald and TD Cowen also lowered their price targets, citing weak core results and policy risks. Barclays remains optimistic with an Overweight rating and a price target of $268.
